From DCAT Value Chain Insights (VCI)
Charles Reay Mackay, Ph.D., will join the company as chief scientific officer for Pfizer’s Inflammation and Immunology Research Unit. Professor Mackay will report directly to José-Carlos Gutiérrez-Ramos, Ph.D., group vice president of BioTherapeutics Research & Development, and will be based in Pfizer’s R&D hub in Cambridge, Massachusetts.
Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was Chair of Diabetes. Professor Mackay has also held important biotech leadership positions at LeukoSite Inc. and Millennium Therapeutics in Cambridge, Massachusetts. He has authored more than 160 peer-reviewed scientific publications and is a member of the Australian Academy of Science and was an Australia Fellow at the National Health and Medical Research Council of Australia.
Inflammation and Immunology is one of Pfizer’s key therapeutic areas. As of February 2015, the Inflammation and Immunology pipeline includes 19 programs from Phase I through registration.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription